Dendreon Plunges on Provenge Revenue Forecast Withdrawal

Dendreon Plunges on Provenge Revenue Forecast Withdrawal — Aug. 4 (Bloomberg) — Dendreon Corp., maker of the prostate-cancer drug Provenge, fell the most in two years after the company withdrew its 2011 revenue esti…

Find More Drug Treatment News Articles Information…